Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 13/20 | 0.53 |
| ▸ | CACNA1A | O00555 | 2/20 | 0.43 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.43 |
| ▸ | CACNB1 | Q02641 | 2/20 | 0.43 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.43 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.43 |
| ▸ | TACR1 | P25103 | 2/20 | 0.40 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.40 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.40 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.40 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.40 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.40 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.40 |
| ▸ | CCR5 | P51681 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3659873 | 0.91 | SLC6A9 (0.63) | SLC6A9CACNA2D1CACNB1CACNA1BCACNA1C | |
| SCHEMBL3664802 | 0.90 | SLC6A9 (0.56) | SLC6A9 | |
| SCHEMBL3661573 | 0.82 | BACE1 (0.49) | SLC6A9CACNA1ACACNA2D1CACNB1CACNA1B | |
| SCHEMBL3664104 | 0.80 | CCR5 (0.47) | SLC6A9CACNA1ACACNA2D1CACNB1CACNA1B | |
| SCHEMBL3660324 | 0.78 | SLC6A9 (0.47) | SLC6A9 | |
| SCHEMBL3658857 | 0.76 | TACR1 (0.43) | SLC6A9CACNA1ACACNA2D1CACNB1CACNA1B | |
| SCHEMBL3664705 | 0.74 | CCR5 (0.46) | TACR1CCR5 | |
| SCHEMBL3663874 | 0.72 | SLC6A9 (0.53) | SLC6A9CACNA2D1CACNB1CACNA1BCACNA1C | |
| SCHEMBL3657250 | 0.71 | SLC6A9 (0.54) | SLC6A9TACR1CCR5 | |
| SCHEMBL3661481 | 0.70 | SLC6A9 (0.47) | SLC6A9CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2231601-A2 | GLYCINE TRANSPORTER-1 INHIBITORS | Amgen, Inc (US) | 2010-09-29 | — | — | EP | claimed |
| WO-2009075857-A2 | GLYCINE TRANSPORTER-1 INHIBITORS | AMGEN INC. (US) | 2009-06-18 | — | — | WO | claimed |
| US-8258306-B2 | Glycine transporter-1 inhibitors | AMGEN INC. (US) | 2012-09-04 | — | — | US | disclosed |
| US-20100298341-A1 | Glycine Transporter-1 Inhibitors | AMGEN INC. | 2010-11-25 | — | — | US | disclosed |
| EP-2231601-A2 | GLYCINE TRANSPORTER-1 INHIBITORS | Amgen, Inc (US) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009075857-A2 | GLYCINE TRANSPORTER-1 INHIBITORS | AMGEN INC. (US) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298341-A1 | Glycine Transporter-1 Inhibitors | SLC18A2, SLC7A11, SLC6A5 | SLC6A9 8/4885CACNA1A 3618/4885CACNA2D1 3216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.